Table 1.
Characteristics of HIV-infected and HIV-uninfected women and men participating in the Women's Interagency HIV Study (WIHS) and Multicenter AIDS Cohort Study (MACS)
| Women (WIHS) | Men (MACS) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HIV+/HAART | HIV+/HAART | ||||||||
| HIV-N=477 | Never N=170 | Ever N=1021 | p-value | HIV-N=309 | Never N=61 | Ever N=489 | p-value | ||
| Age (years) | |||||||||
| <35 | 42% | 24% | 24% | <0.0001 | -- | -- | -- | <0.0001 | |
| 35−39 | 15% | 24% | 21% | -- | -- | -- | |||
| 40−44 | 20% | 19% | 22% | 15% | 21% | 26% | |||
| 45−49 | 12% | 14% | 19% | 22% | 28% | 31% | |||
| 50−54 | 7% | 14% | 10% | 22% | 28% | 24% | |||
| ≥ 55 | 4% | 6% | 5% | 41% | 23% | 20% | |||
| Race/ethnicity | |||||||||
| African-American | 62% | 69% | 56% | 0.005 | 24% | 43% | 27% | 0.04 | |
| Hispanic | 28% | 21% | 31% | 7% | 8% | 8% | |||
| Caucasian/Other | 10% | 11% | 14% | 69% | 49% | 65% | |||
| Education > high school | 35% | 31% | 31% | 0.26 | 83% | 69% | 81% | 0.04 | |
| Annual household income | |||||||||
| <$12K (W) / < $10K (M) | 42% | 51% | 53% | 0.0001 | 16% | 33% | 20% | 0.003 | |
| $12−36K (W)/$10−40K (M) | 43% | 30% | 34% | 27% | 36% | 34% | |||
| ≥ $36K (W) / ≥ $40K(M) | 12% | 18% | 11% | 49% | 26% | 41% | |||
| Not reported | 3% | 1% | 2% | 8% | 5% | 5% | |||
| Current smokers | 50% | 50% | 43% | 0.01 | 27% | 46% | 30% | 0.01 | |
| Alcohol consumption | |||||||||
| None | 36% | 49% | 55% | <0.0001 | 12% | 20% | 20% | <0.0001 | |
| 1−2 drinks/week | 45% | 36% | 35% | 51% | 43% | 58% | |||
| >2 drinks/week | 19% | 14% | 10% | 37% | 38% | 22% | |||
| History of Injection drug use | 20% | 32% | 25% | 0.004 | 7% | 20% | 15% | 0.001 | |
| Family history of MI | 11% | 11% | 14% | 0.20 | 19% | 21% | 26% | 0.04 | |
| METABOLIC RISK FACTORS* | |||||||||
| Diabetes | 11% | 10% | 12% | 0.87 | 15% | 7% | 21% | 0.008 | |
| Used lipid-lowering medication | 1% | 5% | 6% | 0.0003 | 20% | 12% | 30% | 0.0008 | |
| Median BMI (IQR) | 29.3 | 28.2 | 26.6 | <0.0001 | 26.1 | 25.0 | 25.0 | <0.0001 | |
| (24.5−34.4) | (24.3−31.8) | (23.2−31.5) | (23.9−29.3) | (22.5−27.6) | (22.8−27.6) | ||||
| Median systolic BP (IQR) | 116 | 119 | 115 | 0.03 | 124 | 124 | 123 | 0.87 | |
| (108−126) | (109−130) | (107−127) | (117−132) | (117−131) | (116−132) | ||||
| Median LDL-C (IQR) | 97 | 98 | 98 | 0.98 | 116 | 107 | 105 | <0.0001 | |
| (75−120) | (78−120) | (75−123) | (96−142) | (79−123) | (83−128) | ||||
| Median HDL-C (IQR) | 53 | 42 | 46 | <0.0001 | 48 | 42 | 42 | <0.0001 | |
| (43−65) | (30−53) | (37−58) | (40−55) | (34−55) | (36−51) | ||||
| HIV CHARACTERISTICS† | |||||||||
| History of clinical AIDS | -- | 22% | 39% | <0.0001 | -- | 2% | 16% | 0.004 | |
| Median CD4+ T-cells/mm3 (IQR) | |||||||||
| Nadir | -- | 404 | 227 | <0.0001 | -- | 381 | 238 | <0.0001 | |
| (291−538) | (107−349) | (273−565) | (130−344) | ||||||
| Current | -- | 479 | 425 | 0.003 | -- | 484 | 510 | 0.75 | |
| (345−668) | (256−626) | (319−685) | (356−705) | ||||||
| HIV-1 RNA (copies/ml) | |||||||||
| <80 | -- | 20% | 48% | <0.0001 | -- | 12% | 70% | <0.0001 | |
| 80−1000 | -- | 23% | 14% | -- | 15% | 9% | |||
| 1000−10,000 | -- | 26% | 17% | -- | 22% | 9% | |||
| >10,000 | -- | 31% | 21% | -- | 51% | 12% | |||
| Antiretroviral therapy | |||||||||
| Current PI HAART | -- | -- | 46% | -- | -- | 43% | |||
| Current non-PI HAART | -- | -- | 33% | -- | -- | 42% | |||
| Former HAART users | -- | -- | 21% | -- | -- | 15% | |||
*
Metabolic risk factors observed on N=433 HIV- women, N=153 HAART-naïve HIV+ women, N=947 HAART-experienced HIV+ women, N=300 HIV- men, N=57 HAART-naïve HIV+ men, and N=458 HAART-experienced HIV+ men.
†
HIV characteristics observed on N=167 HAART-naïve women, N=1006 HAART-experienced women, N=59 HAART-naïve men, and N=482 HAART-experienced men.
MI, myocardial infarction; BMI, body mass index; BP, blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol